Drug Profile
Obiltoxaximab - Elusys Therapeutics
Alternative Names: Anthim; ETI-204; Obiltoxaximab SFLLatest Information Update: 27 Dec 2022
Price :
$50
*
At a glance
- Originator Elusys Therapeutics
- Class Antibacterials; Antitoxins; Monoclonal antibodies
- Mechanism of Action Anthrax toxin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Anthrax